Although BRCA2-positive women who use tamoxifen may be less likely to develop breast cancer than those using a placebo, BRCA1-positive women derive no protection from the drug.
Although BRCA2-positive women who use tamoxifen may be less likely to develop breast cancer than those using a placebo, BRCA1-positive women derive no protection from the drug.